93-36-7

Basic information

• Product Name: 7-amino-2-naphthol
• Synonyms: 7-amino-2-naphthol;7-aminonaphthalen-2-ol;2-amino-7-naphthol;7-AMINO-2-NAPHTHALENOL;7-Amino-β-naphthol
• CAS NO: 93-36-7
• Molecular Formula: C₁₀H₉NO
• Molecular Weight: 159.18456
• EINECS: 202-241-9
• Mol File: 93-36-7.mol
• Article Data: 7

Chemical Properties

• Melting Point: 201 °C
• Boiling Point: 385.6 °C at 760 mmHg
• Flash Point: 187 °C
• Appearance: /
• Density: 1.281 g/cm³
• Vapor Pressure: 1.69E-06mmHg at 25°C
• Refractive Index: 1.741
• PKA: 9.74±0.40(Predicted)
• CAS DataBase Reference: 7-amino-2-naphthol(CAS DataBase Reference)
• NIST Chemistry Reference: 7-amino-2-naphthol(93-36-7)
• EPA Substance Registry System: 7-amino-2-naphthol(93-36-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 93-36-7(Hazardous Substances Data)

Usage

General Description

7-amino-2-naphthol is a chemical compound also known as 2-naphthol-7-amine or 7-aminonaphthalen-2-ol. It is a derivative of naphthol and is commonly used in the production of dyes and pigments, particularly in the manufacturing of azo dyes. 7-amino-2-naphthol is also utilized in organic synthesis as a reagent for the preparation of various pharmaceuticals and agrochemicals. Additionally, 7-amino-2-naphthol has applications in the field of analytical chemistry, where it is employed in the spectrophotometric determination of metals. Due to its versatile properties and usefulness in various industries, this chemical compound is of significant interest to researchers and manufacturers alike.

InChI:InChI=1/C10H9NO/c11-9-3-1-7-2-4-10(12)6-8(7)5-9/h1-6,12H,11H2

Upstream product

• 875-83-2 sodium 2-naphtholate 
• 135-19-3 β-naphthol 
• 582-17-2 2,7-Dihydroxynaphthalene 
• 7664-41-7 ammonia 
• 91-20-3 naphthalene 
• 613-76-3 2,7-diaminonaphthalene 

Downstream Products

• 613-76-3 2,7-diaminonaphthalene 
• 41363-00-2 7-OH-AT 
• 851773-96-1 7-aminotetralin-2-ol 
• 1361226-17-6 N⁽¹⁾-(4-butylphenyl)-N⁽²⁾-(7-hydroxynaphthalen-2-yl)phthalamide 
• 109091-25-0 N-7-(hydroxynaphthalen-2-yl)benzamide 
• 889884-92-8 toluene-4-sulfonic acid-7-amino-napthalene-2-yl-ester 
• 92287-46-2 2-amino-7-methoxynaphthalene 
• 873387-74-7 2-acetoxy-7-benzoylamino-naphthalene 
• 128542-48-3 2-iodo-7-methoxynaphthalene 

Relevant articles and documents

Altering Fundamental Trends in the Emission of Xanthene Dyes

Fluorescent small molecules enable researchers and clinicians to visualize biological events in living cells, tissues, and organs in real time. Herein, the focus is on the structure and properties of the relatively rare benzo[a]xanthenes that exhibit enhanced steric and electronic interactions due to their annulated structures. Three types of fluorophores were synthesized: (i) pH- and solvent-dependent seminaphthorhodafluors, (ii) pH- and solvent-independent seminaphthorhodafluors, and (iii) pH-independent but solvent-sensitive seminaphthorhodamines. The probes exhibited promising far-red to near-infrared (NIR) emission, large Stoke shifts, broad full width at half-maximum (fwhm), relatively high quantum yields, and utility in immunofluorescence staining. Deviation of the π-system from planarity due to changes in the fluorophore ionization state resulted in fluorescence properties that are atypical of common xanthene dyes.

Inhibitors of checkpoint kinases

The instant invention provides for compounds which comprise fused imidazoles that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.

BICYCLIC AMIDE, CARBAMATE OR UREA DERIVATIVES AS VANILLOID RECEPTOR MODULATORS

This invention relates to bicyclic amide, carbamate or urea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The bicyclic amide, carbamate or urea derivative of the present invention has vanilloid receptor (VR1) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urological diseases or disorders, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor oeractivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD).